Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) just unveiled an announcement.
Biocytogen Pharmaceuticals has established an Audit Committee under its board of directors to enhance corporate governance. This committee is responsible for reviewing financial disclosures, supervising audit work, and ensuring effective internal controls, thereby replacing the need for a board of supervisors.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. operates in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company is incorporated in the People’s Republic of China and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 523,150
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.78B
For a thorough assessment of 2315 stock, go to TipRanks’ Stock Analysis page.